Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm's lead asset, IMCIVREE® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm's headquarters is in Boston, MA.
The fireside chats will be webcasted and available under 'Events & Presentations' in the Investor Relations section of the Company's website at www.rhythmtx.com, and webcast replays will be available for 30 days following the presentations.
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences:
Story Continues
In the European Union and the United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the European Union and the United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
Limitations of Use
Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:
Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign
Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity
Contraindication
Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.
WARNINGS AND PRECAUTIONS
Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.
Depression and Suicidal Ideation: Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.
Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.
Skin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New Melanocytic Nevi: Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.
Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including 'gasping syndrome' can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.
USE IN SPECIFIC POPULATIONS
Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics for information on reporting suspected adverse reactions in Europe.
Please see the full Prescribing Information for additional Important Safety Information.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the safety, efficacy, potential benefits of, and clinical design or progress of any of our products or product candidates at any dosage or in any indication, our participation in upcoming events and presentations, and the date, time and content thereof and the timing of any of the foregoing. Statements using words such as 'expect', 'anticipate', 'believe', 'may', 'will' and similar terms are also forward-looking statements. Such statements are subject to numerous risks, uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors, including those discussed under the caption 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Corporate Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
dconnolly@rhythmtx.com
Media Contact:
Sheryl Seapy
Real Chemistry
(949) 903-4750
sseapy@realchemistry.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make a marketing authorization decision on Moderna's updated COVID-19 vaccine for the 2025-2026 season. "The CHMP's positive opinion on our updated COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1 is an important milestone in our ongoing effort to protect people across the European Union," said Stéphane Bancel, Chief Executive Officer of Moderna. "COVID-19 continues to place a significant burden on vulnerable populations and healthcare systems. Updated vaccines can be an important tool for protecting individuals and societies." The CHMP decision is based on a combination of manufacturing and preclinical data, as well as previous clinical, non-clinical and real-world evidence supporting the efficacy and safety of Moderna's COVID-19 vaccines. The updated vaccine composition aligns with guidance from various global health authorities, which have identified the LP.8.1 strain as an appropriate update to the COVID-19 vaccine composition for the 2025-2026 vaccination season. Additional regulatory applications for Moderna's updated COVID-19 vaccines targeting LP.8.1 are under review around the world. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential authorization by the European Commission of Moderna's COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1; and the opportunity for Moderna to sell COVID-19 vaccines to up to 17 participating European Union countries over a four-year period. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media:Clothilde CailletDirector, Country and Europe Communications Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio


Medscape
2 days ago
- Medscape
EMA Recommends Aqneursa for Niemann-Pick Type C Disease
At its July 2025 meeting, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorization in the European Union for Aqneursa (IntraBio Ireland Ltd) for the treatment of neurologic manifestations of Niemann-Pick type C (NPC) disease. The treatment can be used in combination with miglustat, or as a monotherapy for patients in whom miglustat is not tolerated, in adults and children aged 6 years and older and weighing at least 20 kg, the CHMP said. It also pointed out that miglustat is the only medicine authorized to treat NPC disease and has been shown to slow the general progression of neurologic symptoms in patients. NPC disease is a rare, progressive, and fatal genetic disorder caused by mutations encoding lysosomal proteins that are essential for the intracellular transport and metabolism of body fats, including cholesterol. Over time, the cells of the central nervous system and the body organs stop working. There are no curative therapies for NPC disease. The course of the disease varies highly depending on the age of onset, but most patients with NPC disease are children and die before the age of 20. Improvement in Neurologic Signs, Symptoms, and Functioning The active substance of Aqneursa is levacetylleucine, a modified form of the amino acid leucine that targets underlying processes of neurologic dysfunction. Although the mechanism of action of levacetylleucine is not yet fully understood, nonclinical studies have demonstrated that it corrects energy metabolism. This includes improved production of adenosine triphosphate, the main source of energy for cerebellar tissues and cells. A randomized, double-blind, placebo-controlled, two-period crossover phase 3 study demonstrated that levacetylleucine offered improvement in neurologic signs, symptoms, and functioning — measured using the Scale for the Assessment and Rating of Ataxia — in patients with NPC disease after 12 weeks of treatment compared with placebo. For the study, 60 patients aged 4 years or older with a confirmed diagnosis of NPC disease and at least mild disease-related neurologic symptoms were randomized in a 1:1 ratio to receive either levacetylleucine or placebo for 12 weeks. For the second 12 weeks, patients were switched to the opposite: either placebo or levacetylleucine. At the end of the first 12 weeks, patients treated with levacetylleucine demonstrated a statistically significant improvement compared with those treated with placebo. At the end of the second 12 weeks, patients who switched from levacetylleucine to placebo experienced a significant worsening of symptoms. The only adverse event causally related to treatment with levacetylleucine is flatulence. The drug will be available as 1-g granules for oral suspension. Rob Hicks is a retired National Health Service doctor. A well-known TV and radio broadcaster, he has written several books and has regularly contributed to national newspapers, magazines, and online publications. He is based in the United Kingdom.


Medscape
2 days ago
- Medscape
EMA Says No to Duchenne Gene Therapy Elevidys
At its July 2025 meeting, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use recommended not granting marketing authorization for the Duchenne muscular dystrophy (DMD) gene therapy treatment delandistrogene moxeparvovec (Elevidys, Sarepta Therapeutics). Patients with DMD lack normal dystrophin, found primarily in skeletal and cardiac muscle cells, such that their muscles become progressively weaker and eventually stop working. Elevidys is an adeno-associated virus vector-based gene therapy product for ambulatory patients aged 4 years and older with a confirmed mutation in the DMD gene. It contains the active substance delandistrogene moxeparvovec, made of a virus containing genetic material, to produce a truncated version of dystrophin and thereby slow down disease progression. It is given as a single infusion as a one-time treatment designed to treat the underlying cause of DMD. In making their decision, the EMA said that a study had failed to show that Elevidys had an effect on movement abilities after 12 months. No Significant Improvement The study involved 125 children aged between 4 and 7 years with DMD who were able to walk and who received one infusion of either delandistrogene moxeparvovec or placebo. The main measure of effectiveness was an effect on movement abilities over 12 months, assessed using the North Star Ambulatory Assessment (NSAA). The scale ranges from 0 to 34, with higher scores indicating better movement abilities. Improvements in NSAA scores were observed in patients who received delandistrogene moxeparvovec and placebo. The difference in the change in scores between the two groups was 0.65, which was not statistically significant. In addition, although many patients treated with delandistrogene moxeparvovec were shown to produce a shorter form of the dystrophin protein, the levels of dystrophin could not be linked to an improvement in movement abilities, the EMA said. Acute Liver Failure Deaths In March this year, a 16-year-old boy died from acute liver failure after receiving treatment with Elevidys in December the previous year. In the wake of this — and at the request of the EMA — in April this year, the company temporarily halted clinical studies of the treatment in the EU. Patients who had previously been treated with Elevidys in a clinical trial continued to be monitored. In June, a second patient, aged 15, who had been treated with the drug also died from acute liver failure. Earlier this month, the FDA asked the company to include a "black-box" warning for the risk of acute liver injury and liver failure in patients with DMD who can walk. The EMA said that the company that had applied for a marketing authorization may ask for re-examination of the opinion within 15 days of receiving the agency's opinion. Rob Hicks is a retired National Health Service doctor. A well-known TV and radio broadcaster, he has written several books and has regularly contributed to national newspapers, magazines, and online publications. He is based in the United Kingdom.